Quest Winter 2014 : Page 2

SPORE: Making Strides in Prostate Cancer Research… The SPORE proposes four major projects. Project 1: Impact of germline genetic variants on failure of active surveillance for prostate cancer • Led by Drs. William Catalona, John Witte, Brian Helfand, Charles Brendler, Denise Scholtens, Ramana Davuluri and Jianfeng Xu. • Results from this project will develop criteria to distinguish which patients with clinically localized prostate cancer need immediate treatment versus those who can be managed with active surveillance. Project 2: Glucocorticoid receptor transcriptional activity and the evolution of enzalutamide-resistant Castrate-Resistant Prostate Cancer • Led by Drs. Russell Szmulewitz, Suzanne Conzen, Donald Vander Griend and Walter Stadler. • The development of combination therapies to overcome resistance to hormonal therapy drugs is of paramount clinical importance. human prostate cancer and will implement a clinical trial using a novel drug to treat patients. Project 4: Targeting FoxA1-downstream pathways: a novel therapeutic strategy for Castrate-Resistant Prostate Cancer • Led by Drs. Jindan Yu, Raymond Bergan, Chung Lee and Timothy Kuzel. • This study will shed light on the role of FoxA1 in tumors that no longer respond to hormonal therapy. It will also evaluate targeted therapy that renders the tumors hormone-sensitive again. (Continued from page 1.) T he Prostate Cancer Foundation hosts an annual Scientific Retreat that brings together the brightest minds in prostate cancer research. This year’s retreat took place in October in Carlsbad, California. The SPORE Cores In addition to the research projects, the SPORE has three cores that provide the framework for collaborative research efforts: • Administrative, Leadership Development and Advocacy Core • Biostatistics and Bioinformatics Core • Biospecimen Pathology Core Dr. Catalona and the University of Chicago researchers who collaborate on the SPORE grant attended the retreat. (left to right) William J. Catalona, MD; Geoffrey Greene, PhD; Donald Vander Griend, PhD; Suzanne Conzen, MD, PhD; Walter Stadler, MD; David Vander Weele, MD, PhD; Russell Szmulewitz, MD; Stan Liauw, MD, PhD. The Administrative Core introduces a Leadership Program that will mentor Project 3: EphB4 receptor kinase as a young investigators in developing their target in prostate cancer careers and becoming future SPORE • Led by Drs. Sarki Abdulkadir, cancer research leaders. The SPORE also Parkash Gill and Timothy Kuzel. includes a Developmental Research • This project will develop the Program that provides seed money for receptor tyrosine kinase called innovative pilot projects and a Career EPHB4 as a therapeutic target for Development Program that provides funding The SPORE in Prostate Cancer brings together basic scientists, for young researchers clinicians, pathologists, biostatisticians, bioinformaticists and advocates. Together, they will work through experiments to during the early phases understand the basic biology of prostate cancer and design of their research careers. and conduct innovative paradigm-shifting clinical trials. The SPORE Altogether, if funded, the results obtained through this SPORE will have a significant impact on the outcomes and overall investigators are quality of life of prostate cancer patients. dedicated to fostering Dr. Catalona and the other doctors who were present at the founding meeting of the Prostate Cancer Foundation in 1993 with founder Michael Milken. the careers of junior investigators, serving as mentors to Career Development Project awardees and providing expertise to basic science laboratory investigators who wish to translate basic science results to the clinic. These programs will ensure that new ideas can be explored and future researchers can be developed. The core funds will also support a Patient Advocacy Group. SPORE patient advocates are ambassadors between the SPORE and the larger prostate cancer community. Q uest The mission of the Urological Research Foundation is to support research and patient education in prostate cancer. Q UEST is a free newsletter, but we need and appreciate your voluntary contributions. Q UEST is published three times a year by the Urological Research Foundation. ©2014 Urological Research Foundation No material reproduced without permission. Circulation: 42,000 Medical Editor: William J. Catalona, M.D. Editor: Betsy Haberl Graphics: Amy L. Davis 2 If you are reading Q UEST for the first time and would like to receive future issues, please send your name and address to: Q UEST , PO Box 855, Manchester, MO 63011 . To receive Q UEST by email, please send your request to Find Q UEST online at: Q UEST Winter 2014

Previous Page  Next Page

Publication List
Using a screen reader? Click Here